NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
NAC Attack,针对色素性视网膜炎的 3 期、多中心、随机、安慰剂对照试验
基本信息
- 批准号:10593947
- 负责人:
- 金额:$ 42.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-17 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcetylcysteineAddressAffectAgeAnimal ModelAntioxidantsAreaBiological MarkersBlindnessCaringCause of DeathCell DeathCellsCessation of lifeClinical ResearchClinical TrialsClinical Trials DesignComplementConeConsumptionControlled Clinical TrialsDataDevelopmentDiabetic RetinopathyDiseaseDoseEarly treatmentEyeFeasibility StudiesFutureGenesGenotypeGoalsGrantHealthIndividualIntervention TrialLaboratoriesLegal patentLightMasksMaximum Tolerated DoseMeasuresMedicalMethodologyMissionMutationNIH Program AnnouncementsNational Eye InstituteNatural HistoryOphthalmoscopyOptical Coherence TomographyOpticsOralOutcomeOutcome AssessmentOutcome MeasureOxidative StressOxygenParticipantPathogenicityPatient Outcomes AssessmentsPatientsPerimetryPharmacogenomicsPhasePhase I Clinical TrialsPlacebo ControlPlacebosPlayPopulationProtocols documentationRandomizedReadingRecording of previous eventsResearch PersonnelResearch Project GrantsResearch ProposalsResolutionResourcesRetinaRetinal ConeRetinitis PigmentosaRodRoleSafetySample SizeSampling StudiesScanningSiteSmoking StatusSubgroupSymptomsTestingTimeTreatment EfficacyVisionVisualVisual AcuityVisual FieldsWidthadaptive opticsadaptive optics scanning laser ophthalmoscopycausal variantcomparative efficacyconstrictiondensitydisabilityeffective therapyefficacy testingevidence baseexperiencefovea centralisfunctional outcomesgene therapygenome sequencinggenomic datagroup interventionimprovedinherited retinal degenerationmaculametermosaicmouse modelnew therapeutic targetnon-invasive imagingnoveloral supplementationoxidative damagephotoreceptor degenerationplacebo grouppreventprimary outcomeprogramsrandomized placebo controlled trialresponseretinal rodssextherapeutic targettherapy developmenttomographytreatment durationtreatment groupwhole genome
项目摘要
PROJECT SUMMARY/ABSTRACT
Retinitis pigmentosa (RP), the most common inherited retinal degeneration, causes severe visual
disability and has no effective treatments. It is caused by mutations in one of a large number of genes
that result in rod photoreceptor degeneration while sparing cones. The loss of rods, which constitute
95% of the cells in the outer retina, results in high levels of oxygen causing oxidative stress which is a
major contributor to gradual degeneration of cone photoreceptors. Cone degeneration causes gradual
constriction of visual fields and eventual blindness. Compelling laboratory data demonstrate that
antioxidants, including N-acetylcysteine (NAC), promote cone survival and function in animal models of
RP. A clinical trial testing oral NAC in 30 RP patients showed good safety with a maximum tolerated
dose of 1800 mg bid, which resulted in good intraocular levels and caused small improvements in cone
function over a 6-month treatment period. This has led to the hypothesis that long-term administration
of NAC can promote cone survival and prevent severe visual disability in patients with RP. This project
is a large multicenter, randomized, double-masked, placebo-controlled clinical trial designed to test that
hypothesis. Ellipsoid zone (EZ) width measured on a spectral domain-optical coherent tomography
scan through the fovea corresponds to remaining cones with intact inner and outer segments and thus
is a biomarker for cone survival. Approximately 438 RP patients with an EZ width between 1500 and
8000 µm will be randomized in a 2:1 ratio to 1800 mg NAC bid or placebo. The primary efficacy
objective is to determine if the cumulative loss of EZ width between baseline and month (M) 45 is
significantly less in eyes of subjects in the treatment group versus those in the placebo group.
Secondary efficacy objectives are to determine if reductions between baseline and M45 in mean
macular sensitivity (measured by microperimetry) or best-corrected visual acuity are decreased by NAC
treatment. A novel exploratory outcome will utilize adaptive optics scanning light ophthalmoscopy,
which allows non-invasive imaging of the cone mosaic with single-cell resolution, to determine if
negative changes in cone density, spacing, regularity, and reflectivity between baseline and M45 are
reduced in the intervention group versus the placebo group. All participants will have whole genome
sequencing which will allow pharmacogenomic analyses. The safety and tolerability of long-term NAC
treatment will be carefully assessed. This clinical trial has the potential to identify a new non-invasive,
oral treatment that prevents severe visual disability in patients with RP regardless of the pathogenic
mutation, thereby addressing a major unmet medical need. In addition, it will provide the most definitive
test yet as to whether oxidative damage plays a major role in cone degeneration in patients with RP
and determine if it is a validated therapeutic target for new treatment development.
项目总结/摘要
视网膜色素变性(RP),最常见的遗传性视网膜变性,导致严重的视觉
残疾,没有有效的治疗方法。它是由大量基因中的一个突变引起的
导致视杆细胞退化而保留视锥细胞。燃料棒的损失,
95%的细胞在视网膜外层,导致高水平的氧引起氧化应激,这是一个
锥状光感受器逐渐退化的主要原因。视锥细胞退化导致逐渐
视野缩小最终失明令人信服的实验室数据表明,
抗氧化剂,包括N-乙酰半胱氨酸(NAC),促进视锥细胞的存活和功能,
Rp.一项在30名RP患者中测试口服NAC的临床试验显示出良好的安全性,
剂量为1800 mg bid,导致眼内水平良好,并导致圆锥体略有改善
在6个月的治疗期内发挥作用。这导致了一种假设,即长期管理
NAC可促进RP患者的视锥细胞存活,预防严重视力残疾。这个项目
是一项大型多中心、随机、双盲、安慰剂对照临床试验,旨在检验
假说.在光谱域光学相干层析成像上测量的椭球区(EZ)宽度
通过中央凹的扫描对应于具有完整的内外段的剩余视锥
是视锥细胞存活的生物标志物。大约438名RP患者,EZ宽度在1500和
8000 µm将以2:1的比例随机分配至1800 mg NAC bid或安慰剂组。主要疗效
目的是确定基线和第45个月(M)之间EZ宽度的累积损失是否
与安慰剂组相比,治疗组受试者的眼睛中显著更少。
次要疗效目的是确定基线和M45之间的平均
黄斑敏感度(通过微视野计测量)或最佳矫正视力被NAC降低
治疗一种新的探索性结果将利用自适应光学扫描光检眼镜,
其允许以单细胞分辨率对锥体镶嵌体进行非侵入性成像,以确定是否
在基线和M45之间,锥密度、间距、规则性和反射率的负变化是
与安慰剂组相比,干预组减少了。所有参与者都将拥有全基因组
测序,这将允许药物基因组学分析。长期NAC的安全性和耐受性
治疗将被仔细评估。这项临床试验有可能确定一种新的非侵入性,
预防RP患者严重视力残疾的口服治疗,无论病因如何
突变,从而解决重大未满足的医疗需求。此外,它将提供最明确的
一项关于氧化损伤是否在RP患者的视锥细胞变性中起主要作用的试验尚未进行
并确定它是否是新治疗开发的有效治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter A Campochiaro其他文献
Peter A Campochiaro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter A Campochiaro', 18)}}的其他基金
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
NAC Attack,针对色素性视网膜炎的 3 期、多中心、随机、安慰剂对照试验
- 批准号:
10333382 - 财政年份:2022
- 资助金额:
$ 42.8万 - 项目类别:
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases
一种用于局部治疗视网膜退行性疾病的新型低渗凝胶滴眼剂
- 批准号:
10549354 - 财政年份:2020
- 资助金额:
$ 42.8万 - 项目类别:
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists
工程 VEGF 拮抗剂的脉络膜上非病毒基因转移
- 批准号:
10557124 - 财政年份:2020
- 资助金额:
$ 42.8万 - 项目类别:
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases
一种用于局部治疗视网膜退行性疾病的新型低渗凝胶滴眼剂
- 批准号:
10326840 - 财政年份:2020
- 资助金额:
$ 42.8万 - 项目类别:
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists
工程 VEGF 拮抗剂的脉络膜上非病毒基因转移
- 批准号:
10093050 - 财政年份:2020
- 资助金额:
$ 42.8万 - 项目类别:
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action
整合素结合肽治疗眼部新生血管和黄斑水肿:分子作用机制
- 批准号:
10361561 - 财政年份:2019
- 资助金额:
$ 42.8万 - 项目类别:
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases
治疗性肽持续脉络膜上递送治疗眼部疾病
- 批准号:
9317491 - 财政年份:2016
- 资助金额:
$ 42.8万 - 项目类别:
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye
HIF-1 生物材料抑制剂可长期抗眼部血管生成
- 批准号:
8964295 - 财政年份:2015
- 资助金额:
$ 42.8万 - 项目类别:
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye
HIF-1 生物材料抑制剂可长期抗眼部血管生成
- 批准号:
9256464 - 财政年份:2015
- 资助金额:
$ 42.8万 - 项目类别:
Novel Biodegradable Injectable Rod for Improved AMD Therapy
新型可生物降解注射棒可改善 AMD 治疗
- 批准号:
8647445 - 财政年份:2014
- 资助金额:
$ 42.8万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 42.8万 - 项目类别:
Research Grant